Literature DB >> 23871691

pocrm: an R-package for phase I trials of combinations of agents.

Nolan A Wages1, Nikole Varhegyi.   

Abstract

This paper presents the R package pocrm for implementing and simulating the partial order continual reassessment method (PO-CRM; [1,2]) in Phase I trials of combinations of agents. The aim of this article is to illustrate, through examples of the pocrm package, how the PO-CRM works and how its operating characteristics can inform clinical trial investigators. This should promote the use of the PO-CRM in designing and conducting dose-finding Phase I trials of combinations of agents.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Continual reassessment method; Dose finding; Drug combination; Partial ordering; Phase I trials

Mesh：

Substances：

Year:  2013        PMID： 23871691      PMCID： PMC3775989          DOI： 10.1016/j.cmpb.2013.05.020

Source DB:  PubMed          Journal:  Comput Methods Programs Biomed        ISSN： 0169-2607            Impact factor:   5.428


  10 in total

1.  Retrospective robustness of the continual reassessment method.

Authors:  John O'Quigley; Sarah Zohar
Journal:  J Biopharm Stat       Date:  2010-09       Impact factor: 1.051

2.  A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.

Authors:  X Paoletti; A Kramar
Journal:  Stat Med       Date:  2009-10-30       Impact factor: 2.373

3.  Continual reassessment method: a likelihood approach.

Authors:  J O'Quigley; L Z Shen
Journal:  Biometrics       Date:  1996-06       Impact factor: 2.571

4.  Using the time-to-event continual reassessment method in the presence of partial orders.

Authors:  Nolan A Wages; Mark R Conaway; John O'Quigley
Journal:  Stat Med       Date:  2012-07-17       Impact factor: 2.373

5.  The continual reassessment method in cancer phase I clinical trials: a simulation study.

Authors:  S Chevret
Journal:  Stat Med       Date:  1993-06-30       Impact factor: 2.373

6.  Dose-finding design for multi-drug combinations.

Authors:  Nolan A Wages; Mark R Conaway; John O'Quigley
Journal:  Clin Trials       Date:  2011-06-07       Impact factor: 2.486

7.  Continual reassessment method for partial ordering.

Authors:  Nolan A Wages; Mark R Conaway; John O'Quigley
Journal:  Biometrics       Date:  2011-03-01       Impact factor: 2.571

8.  Interplay of priors and skeletons in two-stage continual reassessment method.

Authors:  Alexia Iasonos; John O'Quigley
Journal:  Stat Med       Date:  2012-08-15       Impact factor: 2.373

9.  Specifications of a continual reassessment method design for phase I trials of combined drugs.

Authors:  Nolan A Wages; Mark R Conaway
Journal:  Pharm Stat       Date:  2013-06-03       Impact factor: 1.894

10.  Model calibration in the continual reassessment method.

Authors:  Shing M Lee
Journal:  Clin Trials       Date:  2009-06       Impact factor: 2.486
  10 in total
  8 in total

1.  A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies.

Authors:  Akihiro Hirakawa; Nolan A Wages; Hiroyuki Sato; Shigeyuki Matsui
Journal:  Stat Med       Date:  2015-05-13       Impact factor: 2.373

Review 2.  Implementation of adaptive methods in early-phase clinical trials.

Authors:  Gina R Petroni; Nolan A Wages; Gautier Paux; Frédéric Dubois
Journal:  Stat Med       Date:  2016-02-29       Impact factor: 2.373

3.  Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology.

Authors:  Philippe B Pierrillas; Sylvain Fouliard; Marylore Chenel; Andrew C Hooker; Lena E Friberg; Mats O Karlsson
Journal:  AAPS J       Date:  2018-03-07       Impact factor: 4.009

4.  CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.

Authors:  Mohamed Amine Bayar; Anastasia Ivanova; Gwénaël Le Teuff
Journal:  Comput Methods Programs Biomed       Date:  2019-05-06       Impact factor: 5.428

Review 5.  Practical designs for Phase I combination studies in oncology.

Authors:  Nolan A Wages; Anastasia Ivanova; Olga Marchenko
Journal:  J Biopharm Stat       Date:  2016       Impact factor: 1.051

6.  Comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by M-K. Riviere, F. Dubois, S. Zohar.

Authors:  Nolan A Wages
Journal:  Stat Med       Date:  2015-01-15       Impact factor: 2.373

7.  A surface-free design for phase I dual-agent combination trials.

Authors:  Pavel Mozgunov; Mauro Gasparini; Thomas Jaki
Journal:  Stat Methods Med Res       Date:  2020-04-27       Impact factor: 3.021

8.  A benchmark for dose-finding studies with unknown ordering.

Authors:  Pavel Mozgunov; Xavier Paoletti; Thomas Jaki
Journal:  Biostatistics       Date:  2022-07-18       Impact factor: 5.279
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.